Depressive symptoms and episodes dominate the course of bipolar disorder. However, the therapeutic armamentarium for bipolar depression is limited. Recent evidence points to the efficacy of second generation antipsychotics (SGAs) for the treatment of bipolar depression. We conducted a systematic review and meta-analysis of the efficacy and safety of SGAs (randomized, double-blind, placebo-controlled trials; used in monotherapy) in the treatment of adult patients with bipolar depression. Publication bias was corrected for by performing similar searches using the clinical trials register of the respective pharmaceutical companies, the Cochrane Database and ClinicalTrials.gov. Seven published papers were identified on the use of aripiprazole, olanzapine and quetiapine. Internal validity of the trials was fairly good, external validity only moderate. Different outcome measures of efficacy and safety were assessed. When the individual trials were looked at, quetiapine and to a lesser extent olanzapine demonstrated significant improvement in MADRS (Montgomery-Å sberg Depression Rating Scale) total scores. This was not demonstrated for aripiprazole. Efficacy was hampered by adverse events, such as weight gain, akathisia and somnolence/sedation. Both clinical heterogeneity of the included trials and statistical heterogeneity of the meta-analytic data were considerable. The number of quetiapine trials was disproportionate to the number of trials of aripiprazole and olanzapine. Further research is needed to assess differential efficacy of the different SGAs and their use in clinical practice.
Introduction
Bipolar disorder is a prevalent disorder, with poor symptomatic and psychosocial outcome (De Fruyt and Demyttenaere, 2007) . About half of the time, bipolar patients are symptomatically ill, with pure depressive symptoms predominating over manic, hypomanic or mixed symptoms (Judd et al., 2002 (Judd et al., , 2003 . Some recent trends in the acute treatment of bipolar depression can be identified. First, the importance of adequate mood stabilization is highlighted, even in the acute treatment phase (De Fruyt and Demyttenaere, 2007) . Second, the use of antidepressants is questioned due to their lack of efficacy, risk of induction of mania and cycle acceleration (Ghaemi et al., 2003; El-Mallakh et al., 2007) . Third, there is a trend to put forward second generation antipsychotics (SGAs) (Calabrese et al., 2005a; Cousins and Young, 2007; Keck Jr, 2005) , which seems to be in line with their proven efficacy in the acute treatment of mania and recent evidence of their prophylactic efficacy (Scherk et al., 2007; Sienaert and De Fruyt, 2007) . This trend is also reflected in current clinical practice guidelines (Yatham et al., 2009 ). However, systematic reviews and meta-analyses addressing the efficacy/effectiveness of SGAs in acute bipolar depression are lacking. Two meta-analyses briefly discussed the efficacy and safety/acceptability of olanzapine and quetiapine monotherapy; more recent data on aripiprazole were not included (Derry and Moore, 2007; Van Lieshout and MacQueen, 2010) . In another meta-analysis (Cruz et al., 2009) , aripiprazole data were included but only efficacy data were analyzed. Therefore, the aim of this paper was to compare the efficacy and safety of SGAs versus placebo, when used in monotherapy for the treatment of bipolar depression.
Methods

Search
We performed a Medline search. We made a selection for Randomized Controlled Trial (RCT) as article type. The titles and abstracts of articles were searched for: ''Bipolar disorder'' (MeSH term, search restricted to major topic headings only) AND (depression OR depressive) AND (amisulpride OR aripiprazole OR clozapine OR olanzapine OR paliperidone OR quetiapine OR risperidone OR ziprasidone OR zotepine). In addition, we hand-searched the references of retrieved papers and key reviews. We identified the corresponding clinical study summaries of the finally selected papers at the clinical trials register of the respective pharmaceutical companies.
For the selected SGAs (for which RCTs were found in the initial Medline search), we performed a similar search using the Cochrane Central Register of Controlled Trials (CENTRAL) database and ClinicalTrials.gov (http://clinical trials.gov). The clinical trials register of the respective pharmaceutical companies were finally checked to further identify trials that were not (yet) published.
Selection
In order to be included, trials had to be randomized, doubleblind, placebo-controlled, and use a SGA in monotherapy to treat adult patients with documented bipolar disorder and a current depressive episode. Title and/or abstracts of selected papers were read and potentially useful reports retrieved in full copy for final selection. Only papers with primary data analysis were included. Decisions on inclusion or exclusion were made by consensus.
Validity assessment
Two of the authors (ED and JDF) independently assessed the quality of the finally selected RCTs using the method described by Jadad et al. (1996) : assessment of randomization, double blinding and description of withdrawals/dropouts, yielding a minimum score of 0 points and a maximum score of 5 points.
Data abstraction
Two of the authors (ED and JDF) independently extracted the data from the trials. Any disagreement was discussed and decisions were documented. The primary source of data was the published papers of the finally selected RCTs. When data were missing or RCTs were not published yet, the clinical study summaries were used.
Quantitative data synthesis
The primary outcome of interest was the mean change in Montgomery-Å sberg Depression Rating Scale (Montgomery and Asberg, 1979) or MADRS score from baseline to endpoint. Secondary outcome measures were rates of response, remission, and dropout due to any cause, dropout due to lack of efficacy, dropout due to adverse events, treatment emergent mania, mean weight gain, clinically significant weight gain, somnolence/sedation/fatigue, akathisia, and extrapyramidal symptoms (EPS).
Efficacy and safety outcomes were combined. For continuous data, a weighted mean difference (WMD) was used as the overall measure of treatment effect, which allows for direct interpretation by readers in common units used in the analyzed studies. Inverse variance weighting was used for pooling. Therefore, the mean values and standard deviations of the continuous outcomes and the number of participants were extracted. When standard deviations were not reported, they were derived from p-values and confidence intervals (CIs), or the mean standard deviations (SDs) of the other studies were used.
For dichotomous outcome data, the relative risk (RR) was estimated, along with its 95% CI. Relative risks, rather than odds ratios, were chosen since they are intuitively better understood by physicians. The RR is normally defined as the risk of an unfavorable event in the intervention group divided by the risk of this event in the control group. Exceptions were made for the response and remission rate, where RR was calculated as the risk of a favorable event in the intervention group divided by the risk of this event in the control group. When treatment was significantly better than control, the number of participants needed to treat (NNT) was reported. NNT is calculated as the reciprocal of the risk difference (RD). Its 95% CI limits are derived as the inverse of the upper and lower limits of the 95% CI of the RD. NNT was rounded up to the next whole number. In case of a negative NNT (i.e. more good events with control than with treatment), the NNT is called the number of participants needed to harm (NNH). NNH was rounded up to the previous whole number.
The DerSimonian-Laird random-effects model was used in all cases, even if heterogeneity was not statistically significant. Random-effects models are, in general, more conservative than fixed-effects models because they take heterogeneity among studies into account. Heterogeneity was determined by a 2 -test, contrasting the RR of the individual trials with the pooled RR. Because statistical tests of heterogeneity have low power, a significance level of 0.1 was used (Petitti, 2001) .
The results for continuous outcome measures are visualized in a forest plot, which shows the confidence interval for each individual study by a horizontal line. The corresponding point estimate is given by a square whose height is inversely proportional to the standard error of the estimate. The statistical analysis was carried out using 'R', free software available at http://www.r-project.org (version 2.8.0). Figures and results for the random-effects (DerSimonian-Laird) meta-analyses were produced in 'R' using the rmeta (Thomas Lumley, 2008, Version 2.14) and the meta (Guido Schwarzer, 2008, Version 0.9-17) library.
Results
Trial flow
A first Medline search was performed on 6 August 2008, and yielded 57 papers, 17 of which reported on the use of a SGA in patients with bipolar depression. One paper (Corya et al., 2006) was an open-label extension study of olanzapine-fluoxetine combination and olanzapine monotherapy. In one paper (Shelton and Stahl, 2004) patients were randomized to risperidone, paroxetine or risperidone-paroxetine combination, added to a mood stabilizer. In one paper (Nierenberg et al., 2006) patients were randomly assigned to open-label adjunctive treatment with risperidone, lamotrigine or inositol. In one paper patients were randomized to olanzapine-fluoxetine combination or lamotrigine. Eight papers (Cookson et al., 2007; Endicott et al., 2007; Hirschfeld et al., 2006; Keck Jr, et al., 2005b; Shi et al., 2004; Tohen et al., 2007; Vieta et al., 2007; Williamson et al., 2006) were secondary analyses. No additional papers were found when the references of retrieved papers and key reviews were looked at. While preparing this manuscript, Medline searches were regularly updated. A final update was performed on 16 December 2009, which yielded 73 papers. No new RCTs were withheld. So, only five papers (Amsterdam and Shults, 2005; Calabrese et al., 2005b; Thase et al., 2006 Thase et al., , 2008 Tohen et al., 2003) fulfilled the aforementioned selection criteria. In the paper of Amsterdam and Shults (2005) patients were randomized to treatment with fluoxetine, olanzapine, olanzapine-fluoxetine combination, or placebo. Primary outcome measure was the relative rates of treatment-emergent manic symptoms. Lithium and valproate was used in 15% of patients. Only nine patients were allocated to treatment with olanzapine: a small sample size in absolute numbers and relative to the other included trials. Furthermore, this paper reported efficacy in box-plot figures, without providing actual numeric data. Therefore, this trial was excluded from the meta-analysis. The clinical study summaries of the four remaining papers were identified at the respective clinical trials registers: aripiprazole trials CN138096 and CN138146 (Thase et al., 2008 ) (Bristol-Myers Squibb, http://ctr.bms.com/ctd/ results.do), olanzapine trial F1D-MC-HGGY (Tohen et al., 2003) (Eli Lilly and Company, http://www.lillytrials.com) and quetiapine trials 5077US/0049 (Calabrese et al., 2005b) and D1447C00135 (Thase et al., 2006) (AstraZeneca, http:// www.astrazenecaclinicaltrials.com).
Three additional trials were found in the AstraZeneca clinical trials register: D1447C00134, D1447C00001, and D144CC00002. While preparing the final version of this manuscript, data of these additional quetiapine trials were published: D1447C00134 , D1447C00001 (Young et al., 2010) and D144CC00002 (Suppes et al., 2010) .
No further trials were identified for aripiprazole, olanzapine and quetiapine in the respective clinical trials registers, CENTRAL database and ClinicalTrials.gov.
In summary, we finally selected seven papers, three of which were not yet published, as of the first phase of our searches and data analysis.
Study characteristics
Five papers (Calabrese et al., 2005b; McElroy et al., 2010; Suppes et al., 2010; Thase et al., 2006; Young et al., 2010) reported on the use of quetiapine. In two of these trials, patients were randomized to quetiapine (300 or 600 mg/day) or placebo (Calabrese et al., 2005b; Thase et al., 2006) . In the third trial patients were randomized to quetiapine (300 or 600 mg/day), paroxetine or placebo. In the fourth trial (Young et al., 2010) patients were randomized to quetiapine (300 or 600 mg/day), lithium or placebo. In the fifth trial (Suppes et al., 2010) patients were randomized to quetiapine sustained-release (300 mg/day) or placebo. This resulted in 5 trial arms of quetiapine 300 mg/day and 4 trial arms of quetiapine 600 mg/day. One paper (Tohen et al., 2003) reported on the use of olanzapine (5-20 mg/day). One paper (Thase et al., 2008) reported on two trials of aripiprazole (5-30 mg/day).
Overall, 2610 patients were randomized to SGAs and 1501 patients to placebo. The mean change in MADRS score from baseline to week 8 was the primary efficacy measure in all studies. Assessments were done weekly in three quetiapine trials (Calabrese et al., 2005b; Suppes et al., 2010; Thase et al., 2006) and the aripiprazole trials (Thase et al., 2008) . In two quetiapine trials Young et al., 2010) , assessments were performed at baseline, weeks 1 and 2, and then every 2 weeks until week 8. In the olanzapine trial no assessments were done on weeks 5 and 7 (Tohen et al., 2003) . Clinical and sociodemographic characteristics are summarized in Table 1 . A more detailed description of selected patients (mainly based upon inclusion and exclusion criteria) is given in Table 2 .
Validity assessment
All trial reports scored 3 points or more when assessed by the method of Jadad et al. (1996) : adequate reporting of randomization, double blinding and withdrawals/dropouts.
Quantitative data synthesis
Efficacy/effectiveness and safety data were analyzed for quetiapine, olanzapine and aripiprazole versus placebo, whenever comparable data were available. The authors decided to separate quetiapine 300 mg and 600 mg. This decision was made a priori and was based upon the clinical profile with expected differences in efficacy and safety. (13) 118 (63) 164 (87) 28 Table 3 summarizes the results of secondary efficacy/effectiveness measures: response, remission, dropout due to lack of efficacy and overall dropout. These dichotomous data are presented as RR and NNT/NNH. Subtle differences were found in the definition of response and remission. In all but one of the trials, response was defined as ! 50% reduction from baseline to endpoint on the MADRS score. In the olanzapine trial (Tohen et al., 2003) , response was defined as ! 50% reduction from baseline to endpoint on the MADRS score and completion of at least four weeks of study. In all the quetiapine trials (Calabrese et al., 2005b; McElroy et al., 2010; Suppes et al., 2010; Thase et al., 2006; Young et al., 2010) , remission was defined as a MADRS score 12 at endpoint. In the olanzapine trial (Tohen et al., 2003) , remission was defined as a MADRS score 12 at endpoint and completion of at least four weeks of study. In the aripiprazole trials (Thase et al., 2008) , remission was defined as a MADRS score 8 at endpoint.
Efficacy/effectiveness
In all trials, drop-out due to ''lack of efficacy'' was described. Additional and overlapping causes of discontinuation were described: ''condition under investigation worsened'' (Suppes et al., 2010) and ''relapsed to depression'' (Tohen et al., 2003) . Only data on ''lack of efficacy'' were used for analysis. Figure 2 summarizes the results on weight gain. Table 4 summarizes the results of other safety measures: clinically significant weight gain (defined as !7% increase from baseline to endpoint), EPS and akathisia, somnolence/ sedation/fatigue, treatment-emergent mania and dropout due to adverse events. These dichotomous data are presented as RR.
Safety
The assessment of EPS and/or akathisia was heterogeneous across the trials. In all quetiapine trials, EPS and akathisia were assessed by the Simpson-Angus Rating Scale (SAS) and the Barnes Akathisia Rating Scale (BARS) (Calabrese et al., 2005b; McElroy et al., 2010; Suppes et al., 2010; Thase et al., 2006; Young et al., 2010) . In one trial , an additional scale was used: the Abnormal Involuntary Movement Scale (AIMS). However, these quetiapine trials differed in the final reporting of rating scale scores: mean change in SAS from baseline (Calabrese et al., 2005b; Thase et al., 2006; Young et al., 2010) , number of patients with an increase in SAS from baseline (Calabrese et al., 2005b; McElroy et al., 2010) , mean change in BARS from baseline (Calabrese et al., 2005b; McElroy et al., 2010; Young et al., 2010) , mean BARS score at last assessment (Thase et al., 2006) , number of patients with an increase from baseline (Thase et al., 2006) , and number of patients with ''no change'' or ''improvement'' in SAS and BARS scores from baseline (Suppes et al., 2010) . In all quetiapine trials the standardized assessments were supplemented by a mentioning of adverse events ''considered to be EPS'' (Calabrese et al., 2005b; Thase et al., 2006) or adverse events ''potentially associated with EPS'' Suppes et al., 2010; Young et al., 2010) . It was not In the clinical report of Calabrese et al. (2005b) , rates of akathisia were reported, but these rates were not reported in the published paper. In the clinical trial report of Thase et al. (2006) , rates of ''extrapyramidal disorder'' were reported; however, these rates differed from the rates of adverse events ''considered to be EPS'' that were presented in the published paper.
In the olanzapine trial (Tohen et al., 2003) , EPS was assessed by the SAS and the AIMS. In the published paper, it was only reported that ''the mean change in and emergence of EPS were low, with no statistical differences across treatment groups''. The percentage of patients who used antimuscarinic medications at least once during the trial was also mentioned. In the clinical trial report, rates of treatmentemergent parkinsonism and dyskinesia were mentioned. These rates were based on the changes in SAS and AIMS.
In the aripiprazole trials (Thase et al., 2006) , EPS was assessed using the SAS, AIMS and BARS. Overall rates of ''EPS-related adverse events'' were reported, as well as more specific rates of akathisia and ''EPS-related adverse events other than akathisia''. Also reported were changes from baseline to endpoint in SAS, AIMS and BARS scores.
In order to have a homogeneous assessment of EPS, only data for quetiapine (Calabrese et al., 2005b -15/-11.9 -11.94/-10.61 -12.34/-11.46 -4.07 (-6.03; -2.11) -4.29 (-6.28; -2.3) -3.71 (-6.22; -1.2) -6.13 (-8.33 ; -3.93) -5.01 (-6.95; -3.07) -3.55 (-5.55; -1.55) -3.59 (-6.1; -1.08) -5.51 (-7.88; -3.14) Heterogeneity: Q = 0.07; p = 0.787 Heterogeneity: Q = 25.38; p = 0.008
Overall: Z = -7.71; p = 0; n = 1396
Overall: Z = -9.37; p = 0; n = 1661
Overall: Z = -1.31; p = 0.191; n = 690
Overall: Z = -8.43; p = 0; n = 3873 2010; Suppes et al., 2010; Thase et al., 2006; Young et al., 2010) and aripiprazole (Thase et al., 2008 ) could be used: ''adverse events considered to be EPS''/''adverse events potentially associated with EPS'' and ''EPS-related adverse events'', respectively. Likewise, in order to have a homogeneous assessment of akathisia, only limited data for quetiapine (Calabrese et al., 2005b) and aripiprazole (Thase et al., 2008) were used. In all trials, somnolence/fatigue/asthenia/sedation were assessed. However, not all trials reported on all these different adverse events, nor was it stated how these overlapping adverse events were defined.
All SGAs pooled
In the quetiapine trials (Calabrese et al., 2005b; McElroy et al., 2010; Suppes et al., 2010; Thase et al., 2006; Young et al., 2010) , treatment-emergent mania was defined as a Young Mania Rating Scale (YMRS) score of !16 on any two consecutive visits or at the final assessment, or an adverse event of mania or hypomania. In the olanzapine trial (Tohen et al., 2003) , treatment-emergent mania was defined as a YMRS score of <15 at baseline and !15 at any time thereafter. Treatment-emergent mania (with also data for mixed episodes) was not clearly defined in the aripiprazole trials (Thase et al., 2008) . For aripiprazole combined data were used for mania and mixed episodes.
Discussion
This systematic review and meta-analysis studied the efficacy and safety of SGAs, which are used in monotherapy for the treatment of patients with bipolar depression. This paper adds to previous meta-analyses by the inclusion of new reports on quetiapine and aripiprazole and the extensive assessment of both efficacy and safety. The authors have tried to minimize the problem of publication bias by not limiting the search to published papers (Medline) only; searches were also performed using the clinical trials register of the respective pharmaceutical companies, the Cochrane Central Register of Controlled Trials database and ClinicalTrials.gov. Heterogeneity: Q = 0.71; p = 0.87 Overall: Z = 6.69; p = 0; n = 1461 Heterogeneity: Q = 3.79; p = 0.436 Overall: Z = 6.12; p = 0; n = 1690
Study
Mean change from baseline
Heterogeneity: Q = 0.19; p = 0.66
Overall: Z = 0.51; p = 0.611; n = 727 Heterogeneity: Q = 71.92; p = 0 Overall: Z = 4.04; p = 0; n = 3978
All SGAs pooled Seven papers were identified: one paper on the use of aripiprazole (two trials), one paper on the use of olanzapine and five papers on the use of quetiapine (5 trial arms of quetiapine 300 mg/day, 4 trial arms of quetiapine 600 mg/day). All these trials were sponsored by the pharmaceutical industry. We could not identify any published reports on the use of amisulpride, clozapine, paliperidone, risperidone, ziprasidone or zotepine. For ziprasidone, two trials were found in the clinical trials register of Pfizer: 6-week, double-blind, placebo-controlled in patients with bipolar I depression. In neither trial was superiority over placebo found, as measured by MADRS total score mean change from baseline. These data were not (yet) published when finalizing the manuscript. Overall, 4111 patients were included: 2610 patients were randomized to SGAs and 1501 to placebo. The average patient was middle aged, Caucasian, moderately depressed and treated in an outpatient setting.
The absolute number of included trials was limited and the relative number of quetiapine trials versus trials of olanzapine and aripiprazole was disproportionate: a major limitation for meta-analytic purposes. However, the small number of included trials made it possible to have a closer look at different inclusion and exclusion criteria, and subtle nuances in the assessment of efficacy and safety. These issues pertain to the external validity of RCTs and the meta-analytic merging of data that were not a priori produced for this purpose: issues that are often and inevitably overlooked in large-scale meta-analyses.
Internal validity of the included trials was fairly good, as all trial reports scored !3 points, when assessed by the method of Jadad et al. (1996) . External validity was only moderate, since information on recruitment procedure, treatment setting, duration of the current depressive episode, previous antidepressant treatment, previous treatment with mood stabilizers was limited to absent.
When the individual trials were looked at, quetiapine (at both 300 mg and 600 mg) and to a lesser extent olanzapine demonstrated significant improvement in the MADRS total scores from baseline to endpoint: the primary efficacy endpoint. This was not demonstrated for aripiprazole. Similar results were found for response and remission rates. Important side effects were as could be expected from former RCTs and clinical practice: weight gain (olanzapine, to a lesser extent quetiapine), akathisia (aripiprazole), somnolence (olanzapine and quetiapine 300 and 600 mg), sedation (quetiapine 300 mg and 600 mg), low rates of EPS and fatigue. The results of weight gain should be interpreted with caution considering the short duration of the trials. As with schizophrenia, patients with bipolar disorder treated with SGAs have an increased risk for a metabolic syndrome (Correll et al., 2008; Fagiolini et al., 2008; Newcomer, 2007) ; weight gain and other metabolic issues should be evaluated in the longer term. For those SGAs with proven efficacy, the NNH for somnolence/sedation was within the same range (or even lower) as the NNT for response and remission: a rather unfavourable risk/benefit ratio. However, these findings should be interpreted with caution, as only limited information is given on the persistence and severity of these side effects.
When meta-analyzed, SGAs as a group were significantly better than placebo in four out of five outcome measures of efficacy: WMD, response, remission and dropout due to inefficacy. Adverse events, significantly more associated with SGAs than with placebo, were (clinically significant) weight gain, EPS, akathisia, somnolence, sedation, fatigue, and dropout due to adverse events. However, statistical heterogeneity (Q and corresponding p-value) was found for most efficacy and some safety measures: MADRS mean change from baseline to endpoint, remission, global dropout, inefficacy dropout, weight gain, clinically significant weight gain, and somnolence.
Besides the many different sources of clinical heterogeneity, as discussed below, differences in the studied drugs should be considered as the primary source of heterogeneity. Although SGAs are often considered as a group for metaanalysis (schizophrenia, mania and unipolar depression), SGAs are not alike and represent in themselves an important source of heterogeneity (Leucht et al., 2009; Papakostas et al., 2007; Scherk et al., 2007) . This seems true when inspecting the forest plots for WMD (MADRS mean change from baseline to endpoint, weight gain) and the RRs (different efficacy and safety measures): for example, non overlapping 95% CI for quetiapine (300 mg and 600 mg) versus aripiprazole in MADRS score mean change from baseline, for (clinically significant) weight gain (olanzapine vs quetiapine 300 mg and 600 mg and aripiprazole), global dropout (olanzapine vs aripiprazole).
These results regarding differential efficacy and safety should be interpreted with caution as the primary purpose of a meta-analysis still is the pooling and not the dissecting of data. Furthermore, for a better comparison of the different SGAs, more trials with olanzapine and aripiprazole are needed. Duration of the trials was short and the question remains as to how the differential efficacy/effectiveness (SGAs versus placebo) evolves over time. In a subgroup of bipolar II patients treated with quetiapine, the change in MADRS score from baseline to endpoint was statistically superior to placebo at most assessments, but did not reach statistical significance at final assessment (Calabrese et al., 2005b) . Likewise, statistical significance favouring aripiprazole was observed during weeks 1 to 6 (trial 1) and weeks 1 to 5 (trial 2) and was only lost during longer treatment (Thase et al., 2008) . Another question, which could not be answered owing to the nature of the studied trials (SGAs in monotherapy), was the differential efficacy (vs placebo) of SGAs when added to an ongoing treatment with a mood stabilizer. For antidepressants this differential efficacy is limited to absent (Nemeroff et al., 2001; Sachs et al., 2007) .
Direct evidence of clinical heterogeneity is found in the clinical samples (e.g. number of bipolar II patients, number of patients with a rapid cycling course), the large variation of baseline mean MADRS score (26.5 to 32.6), and number of patient contacts. In the olanzapine and aripiprazole trials, only bipolar I patients were included. In the quetiapine trials, both bipolar I and II patients were included. Bipolar II patients were only included in the quetiapine trials. One trial on quetiapine found a lower efficacy in bipolar II than in bipolar I patients (Calabrese et al., 2005b) . The advantage of antidepressant agents over placebo is higher in more severely depressed patients, as has been shown for antidepressants (Kirsch et al., 2008) and lamotrigine (Geddes et al., 2009) . A higher number of patient contacts is associated with a higher therapeutic impact (Posternak and Zimmerman, 2007) . Therefore, most of these differences are a potential source of heterogeneity.
Heterogeneity is also found in the only partially overlapping definitions of efficacy/effectiveness and safety measures. This latter source of heterogeneity is avoidable and thereby a missed opportunity. Researchers should strive for a better consensus of the definition, use and reporting of outcome measures.
Indirect evidence of heterogeneity is found in the large variation of placebo event rate for most efficacy measures: response (30%-56%), remission (25%-55%), global dropout (28%-62%) and inefficacy dropout (5%-32%). These differences are large for an identical placebo condition and could be explained by known (or unknown) clinical or methodological differences. The complexity of heterogeneity is further highlighted when comparing (visual inspection of the forest plot for MADRS mean change from baseline to endpoint; Figure 1 ) two quetiapine trials (Calabrese et al., 2005b; Thase et al., 2006; ) with identical study design: differences for efficacy were found to be higher between different studies (for same dose) than between different doses (for same study).
Conclusion
This systematic review has found a considerable amount of data regarding the use of SGAs (in monotherapy) in patients with bipolar depression. Efficacy/effectiveness was found for quetiapine and to a lesser extent olanzapine. In a meta-analytic data analysis of this evidence, SGAs proved to have a superior efficacy versus placebo. However, clinical and statistical heterogeneity was high. An antidepressant 'class effect' of SGAs could not be confirmed. Side effects may hamper their clinical use: somnolence, sedation, akathisia, weight gain and other metabolic problems. Despite these limitations, SGAs like quetiapine and olanzapine have a place in the treatment of patients with bipolar depression, for whom treatment options are rather limited (until now mainly adequate mood stabilization, antidepressants and electroconvulsive therapy). Issues that certainly warrant further research are the impact of depression severity at baseline, the antidepressant efficacy/ effectiveness beyond the acute phase, the efficacy/effectiveness when added to a mood stabilizer and the long-term follow-up of side effects. This research and further clinical experience have to make clear which patients are most likely to benefit and which patients have the best risk/benefit ratio. SGAs (in particular quetiapine and olanzapine) have succeeded in their first 'trial' (i.e. RCTs and evidence based psychiatry) and should now be submitted to their second trial (i.e. careful application and evaluation in real-life clinical practice) (Healy, 2009 ). This meta-analysis further highlights the important differences among SGAs: an overarching category of compounds with different mechanisms of action and clinical usefulness.
From a more methodological point of view, this review highlights how clinical trials are designed in an idiosyncratic way: unclear description of included patients, (subtle) differences in inclusion and exclusion criteria, procedures, assessment of efficacy and safety, etc. The external validity of trials is thereby limited and individual trials are still difficult to compare.
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